Lorantis Raises $42 Million In Series C
10/19/2005 5:10:47 PM
Lorantis, an immunology drug discovery and development company, announced today the closing of a 25 Pounds ($42) million series C private financing round led by Funds advised by Apax Partners. Apax Partners Funds were joined in this financing round by existing investors Abingworth Management, JP Morgan Partners, Quester Capital Management, Schroder Ventures, The Wellcome Trust and funds managed by Fleming Family and Partners. The investment will enable the clinical development programmes to begin on the Company's innovative products for the treatment of immune diseases, such as allergy, arthritis and transplantation, as well as supporting new lines of research.
comments powered by